Molecular Surveillance of Chronic Myeloid Leukemia Patients in the Imatinib Era–Evaluation of Response and Resistance
P Paschka, K Merx, A Hochhaus - Acta haematologica, 2004 - karger.com
Residual disease in chronic myeloid leukemia patients may be assessed by various
molecular methods. After imatinib treatment a significant proportion of patients achieve …
molecular methods. After imatinib treatment a significant proportion of patients achieve …
[HTML][HTML] Molecular response after 3 months of 1st line imatinib therapy is predictive for treatment failure and disease progression in patients with chronic phase chronic …
B Hanfstein, MC Müller, P Erben, S Schnittger… - Blood, 2010 - Elsevier
Abstract Abstract 360 Introduction: The lack of a sufficient response to first line imatinib
treatment has been observed in a substantial proportion of CML patients and has been …
treatment has been observed in a substantial proportion of CML patients and has been …
Assessment of the response to imatinib in chronic myeloid leukemia patients–comparison between the FISH, multiplex and RT‐PCR methods
P Raanani, I Ben‐Bassat, S Gan… - European journal of …, 2004 - Wiley Online Library
Objective: The objective of this study was to evaluate the kinetics of molecular response in
chronic myeloid leukemia (CML) patients treated with imatinib and to compare between the …
chronic myeloid leukemia (CML) patients treated with imatinib and to compare between the …
The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any …
DDM Ross, A Grigg, A Schwarer, C Arthur, K Loftus… - Blood, 2008 - Elsevier
After 5 years of imatinib treatment 40–50% of chronic myeloid leukaemia (CML) patients will
have stable undetectable BCR-ABL by real-time quantitative RT-PCR (RQ-PCR) using strict …
have stable undetectable BCR-ABL by real-time quantitative RT-PCR (RQ-PCR) using strict …
[HTML][HTML] Molecular response to first line imatinib therapy is predictive for long term event free survival in patients with chronic phase chronic myelogenous leukemia–an …
MC Müller, B Hanfstein, P Erben, S Schnittger… - Blood, 2008 - Elsevier
The introduction of imatinib has significantly changed prognosis of CML patients. Despite
favourable hematologic and cytogenetic response (CyR) data, patients (pts) on first line …
favourable hematologic and cytogenetic response (CyR) data, patients (pts) on first line …
[HTML][HTML] A More Sensitive RQ-PCR to Assess Complete Molecular Remission Does Not Allow the Prediction of Relapse After Discontinuation of Imatinib In Chronic …
FX Mahon, S Dulucq, F Guilhot, L Legros, P Rousselot… - Blood, 2010 - Elsevier
Abstract 2298 We previously reported that imatinib treatment could be safely discontinued in
chronic myeloid leukemia (CML) patients who had achieved a sustained complete …
chronic myeloid leukemia (CML) patients who had achieved a sustained complete …
Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at …
C Pavlovsky, I Giere, B Moiraghi, MA Pavlovsky… - … Myeloma and Leukemia, 2011 - Elsevier
Background Monitoring minimal residual disease (MRD) by real-time quantitative
polymerase chain reaction (RT-PCR) in chronic myeloid leukemia (CML) patients is …
polymerase chain reaction (RT-PCR) in chronic myeloid leukemia (CML) patients is …
[HTML][HTML] The risk of relapse in CML patients who discontinued imatinib can be predicted based on patients age and the results of dPCR analysis
S Mori, E Vagge, P le Coutre, E Abruzzese, B Martino… - Blood, 2014 - Elsevier
Introduction. Chronic myeloid leukemia (CML) patients (pts) treated with imatinib first line
achieve complete cytogenetic response (CCyR) in> 70% of cases and major molecular …
achieve complete cytogenetic response (CCyR) in> 70% of cases and major molecular …
Early molecular response in chronic myeloid leukemia patients predicts future response status
S Kagita, S Jiwtani, S Uppalapati, VG Linga, S Gundeti… - Tumor Biology, 2014 - Springer
Imatinib is the frontline therapy for chronic myeloid leukemia (CML) management. Most of
the CML patients achieve major responses, but a proportion (nearly 25–35%) of them …
the CML patients achieve major responses, but a proportion (nearly 25–35%) of them …
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for …
D Marin, J Kaeda, R Szydlo, S Saunders, A Fleming… - Leukemia, 2005 - nature.com
We monitored BCR–ABL transcript levels by quantitative real-time PCR in 103 patients
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …